Cambridge and Farnborough, UK, 15 January 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leader in the industry for the design and manufacture of automated laboratory equipment, will collaborate to offer automated micro-plate handling capabilities for single cell analysis.
Wickham Laboratories are excited to announce their most recent publication on “The Importance of Testing for Pyrogens in Raw and In-Process Materials”, written by Section Head of Endotoxin and Cytotoxicity Testing, Sophie Bell.
Arecor Limited, the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides enabling the improved treatment of diabetes and other conditions, is pleased to announce its participation at PEPTalk 2019’s Protein Science Week. This leading international conference and one of the largest annual gatherings of over 1,300 protein science researchers in the world, will be held between January 14-18, 2019, at the Hilton Hotel, San Diego Bayfront, San Diego, California, USA.
Cambridge, UK., 4 January 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company
leveraging its innovative and proprietary formulation technology to develop superior treatments for a
range of disease areas, including diabetes, is pleased to announce that the Company has filed a Clinical
Trial Application (“CTA”) to conduct a Phase I study in Type 1 patients of its ultra-rapid acting insulin
product, AT247. This novel formulation of prandial insulin is designed to deliver an acceleration of
insulin absorption post injection.
Cambridge, UK, January 3rd 2019: Owlstone Medical (or the “Company”), a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Cancer Research UK, today announces the clinical launch of the PAN Cancer trial for Early Detection of Cancer in Breath1, with the first patients now being recruited for the 1,500 patient study.
Prof David Klenerman and Prof Andrew Briggs appointed as scientific advisors
CAMBRIDGE, UK, 20 December 2018 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to scalable and high-fidelity gene synthesis, today announces the formation of its scientific advisory board (SAB). Evonetix has appointed Prof David Klenerman FMedSci FRS and Prof Andrew Briggs to advise the Company on key focus areas in synthetic biology and bioethics, to support the development of its novel DNA synthesis platform.
Cambridge, UK, 17 December 2018: Horizon Discovery Group plc (AIM: HZD), a global leader in the application of gene editing and gene modulation technologies, today announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc (AIM: C4XD) ("C4XD"), a pioneering drug discovery company.
Dr Jose Saro joins Avacta from Roche to lead the Group’s Affimer® therapeutic development strategy and drive the in-house programmes into the clinic
Cambridge, UK, 12 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Dr Jose Saro has been appointed as Chief Medical Officer to lead the Group’s therapeutic development strategy and drive the in-house programmes into the clinic.
Click below to read:
Cambridge, UK and Seoul, South Korea, 10 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and LG Chem Life Sciences, the life sciences division of the South Korean LG Group, today announced a multi-target collaboration and development agreement. The agreement provides LG Chem with the exclusive rights to develop and commercialize, on a worldwide basis, multiple Affimer® therapeutics intended for treatment of patients in the fields of inflammatory disorders, and oncology.